Last updated on April 2019

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Other Details:

For more information, please contact Incyte Corporation at 1.855.463.3463

Find a site near you

Start Over

Research Center

Located in: Miami Beach, FL USA
  Connect »

Mount Sinai Medical Center

Located in: Miami Beach, FL United States
  Connect »